Testing Healthy Participants for Drowsiness After Single Dosing of Two Different Doses of Muscle Relaxer
A Prospective, Randomized, Single-blind, Study to Assess Drowsiness, Cognition, Fall Risk, and Electroencephalographic (EEG) Dynamics After Oral Metaxalone Tablets 640 mg (M640) Versus Metaxalone 800 mg in Healthy Participants
Health participants take a single dose, perform testing, washout for one week, take a single dose of different formulation, and perform testing for comparison of the 2 doses.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Healthy participants will take one dose of a drug after eating a meal. When the drug is at the highest level in their blood, testing for drowsiness and the risk of falling will take place. Brain wave monitoring known as an EEG will take place throughout the testing. Participants will take a second dose of the drug with the same testing one week later.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Project Manager
- Phone Number: 480-483-1410
- Email: mshahbandar@primusrx.com
Study Contact Backup
- Name: Clinical Manager
- Phone Number: 480-250-6689
- Email: msanstead@primusrx.com
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43213
- Recruiting
- AMR Clinical - Columbus
-
Contact:
- Site Manager
- Phone Number: 614-683-5800
- Email: jim.sanders@amr-clinical.com
-
Contact:
- Study Coordinator
- Phone Number: 614-683-5800
- Email: kim.burmane@amr-clinical.com
-
Principal Investigator:
- Harold Green, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adults aged 18 to 55 years old
- Weigh at least 120 pounds
- Medically healthy
- Able to sign and date informed consent form
Exclusion Criteria:
- Current use of any medications known to affect the sleep-wake cycle
- Sleep disorder diagnosis
- Positive urine test for drugs
- Known history of alcohol use disorder
- Having a history of cognitive disorders, depression, schizophrenia, panic disorder, or dementia
- Having difficulty eating high fat meal
- Participants who are pregnant, nursing or intending to become pregnant during the period of study.
- Blood Pressure > 160/110 or <90/50 mmHg.
- Heart Rate >100 or < 50/ beats per minute.
- Having a history of seizure disorder or epilepsy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active metaxalone m640 mg
One dose administered after a standard meal with testing Baseline dose to time of maximum concentration (Tmax) |
Dose micronized 640 mg
Other Names:
|
|
Active Comparator: Active metaxalone 800 mg
One dose administered after a standard meal with testing Baseline dose to time of maximum concentration (Tmax) |
The dose is 800 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline to approximately 4 hours post-dose, in mean reaction time to a stimulus as measured in milliseconds by the Reaction Time Test (RTT)
Time Frame: Baseline dose to four (4 ) hours post-dose
|
Measures the time between a visual stimulus and response, measured in milliseconds |
Baseline dose to four (4 ) hours post-dose
|
|
Change from baseline to approximately 4 hours post-dose of delayed response exceeding a predefined threshold >300 ms as measured by the Reaction Time Test (RTT)
Time Frame: Baseline dose to approximately 4 hours post-dose
|
measures the time between a visual stimulus and response, measured in milliseconds |
Baseline dose to approximately 4 hours post-dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: James Lukban, D.O., Primus Pharmaceutical, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PMMD-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
No plan for publication at this time.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.